Reply to "Rituximab versus cyclophosphamide for remission induction in active, severe ANCA ‐associated vasculitis"

AbstractWe appreciate the insights and concerns shared by Dr. Jain et al. regarding the use of rituximab (RTX) and cyclophosphamide (CYC) for the treatment of granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), as outlined in the American College of Rheumatology/Vasculitis Foundation (ACR/VF) guideline for the treatment of ANCA-associated vasculitis (AAV) [1]. These concerns are timely given the ongoing COVID-19 pandemic.

https://onlinelibrary.wiley.com/doi/10.1002/art.41991?af=R

Source: Arthritis and Rheumatology - October 4, 2021 Category: Rheumatology Authors: Sharon A. Chung, Philip Seo, Peter A. Merkel, Carol A. Langford Tags: REPLY Source Type: research